Notizie AIOM – anno XV
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation ...Leggi tutto
Health-Related Quality of Life in Adolescent and Young Adult Patients With Cancer: A Longitudinal Study
To examine changes in health-related quality of life (HRQoL) and its predictors during the first 2 years after initial cancer diagnosis in adolescent and young adult (AYA) patients with cancer. A multicenter, longitudinal, prospective study was conducted among a diverse ...Leggi tutto
Discussing molecular testing in oncology care: Comparing patient and physician information preferences
Molecular testing to inform treatment and clinical trial choices is now the standard of care for several types of cancer. However, no established guidelines exist for the type of information physicians should cover during discussions with the patient about the test or its ...Leggi tutto
ASCP/CAP/AMP/ASCO Clinical Practice Guideline Focuses on Molecular Biomarker Testing for Patients With Colorectal Cancer
February 7th, 2017 - A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes. The American Society for Clinical Pathology (ASCP), the College of American ...Leggi tutto
Clinical Benefit, Price and Approval Characteristics of FDA-approved New Drugs for Treating Advanced Solid Cancer, 2000-2015
Prices of anti-cancer drugs are skyrocking. We aimed to assess the clinical benefit of new drugs for treating advanced solid tumors at the time of their approval by the US Food and Drug Administration (FDA) and to search for a relation between price and clinical benefit ...Leggi tutto
Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection?
The recent article in Journal of Clinical Oncology by Hanna et al discussed the issue of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) in the era of targeted therapy (TT). The article showed similar results in mRCC after CN and immunotherapy (eg, ...Leggi tutto